about
Role of ran binding protein 5 in nuclear import and assembly of the influenza virus RNA polymerase complexFunctional association between viral and cellular transcription during influenza virus infection.The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.A promoter mutation in the haemagglutinin segment of influenza A virus generates an effective candidate live attenuated vaccineComparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicityCONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement.The development of vaccine viruses against pandemic A(H1N1) influenza.Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules.Developing vaccines to combat pandemic influenzaAn additional oligosaccharide moiety in the HA of a pandemic influenza H1N1 candidate vaccine virus confers increased antigen yield in eggs.Permissible variation in the 3' non-coding region of the haemagglutinin genome segment of the H5N1 candidate influenza vaccine virus NIBRG-14 [corrected].The consortium for the standardization of influenza seroepidemiology (CONSISE): a global partnership to standardize influenza seroepidemiology and develop influenza investigation protocols to inform public health policy.Workshop report: Immunoassay standardisation for "universal" influenza vaccines.WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 201International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISEThe Ability of a Non-Egg Adapted (Cell-Like) A(H1N1)pdm09 Virus to Egg-Adapt at HA Loci Other than 222 and 223 and Its Effect on the Yield of Viral Protein.Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.Many ways to make an influenza virus--review of influenza virus reverse genetics methods.Characterization of the interaction between the influenza A virus polymerase subunit PB1 and the host nuclear import factor Ran-binding protein 5.Association of the influenza A virus RNA-dependent RNA polymerase with cellular RNA polymerase II.WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 20Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards.Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1).Influenza virus inhibits RNA polymerase II elongation.Mx1 GTPase accumulates in distinct nuclear domains and inhibits influenza A virus in cells that lack promyelocytic leukaemia protein nuclear bodies.Correction: Permissible Variation in the 3′ Non-Coding Region of the Haemagglutinin Genome Segment of the H5N1 Candidate Influenza Vaccine Cirus NIBRG-14.Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016.The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML.Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere seasonWorkshop report: Experimental animal models for universal influenza vaccinesCross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza VaccinesMutation of influenza A virus PA-X decreases pathogenicity in chicken embryos and can increase the yield of reassortant candidate vaccine virusesCross-protective immune responses induced by sequential influenza virus infection and by sequential vaccination with inactivated influenza vaccinesCross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of ImmunizationImproved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules
P50
Q24673668-FB59F651-666E-4482-810E-6D4FF90BF370Q27863933-F2F7CA5F-C719-462E-8397-762790D690AEQ30365366-718C86AB-7E0C-4D45-8EA8-CC6107B36A43Q30365396-946AAE66-E5DA-40D2-AE94-EC412ECD3B4BQ30382921-F2D2A10D-356C-4EF8-9CE2-C1D2435F1BC3Q30390554-0771401B-B7F6-438E-9F61-B0A4E8F052BEQ30398053-626C129B-AD94-4F94-80F2-C4AC6187A33EQ30401820-AE9EFC3F-19FE-45C3-BE7B-03AF416750F0Q30408108-31828582-3BA4-4DEF-B712-C63E0E27B75EQ30410219-A56A5DAA-9E96-4E2D-81AB-D502CB12D716Q30416922-48DD59F4-A183-491A-926A-3CD0FDFC843EQ30425378-D59BF58E-EA2E-4189-BB9C-782EC8CAFF80Q33619871-66E1E65C-8F62-4EEF-B15E-C6C21BD14D8BQ34295635-905212A7-3514-4985-96E2-C6C39A2C22ABQ35901999-97C64752-FE24-40D7-BED5-469787AA7661Q36197334-6EFE154E-B6FB-4DEB-861D-32BFBCCEBE06Q37444287-15A6089A-4849-4C32-95A7-6276791938D3Q38019971-45984039-1E06-4C36-9BE4-3025395AF67CQ39544562-4096EDC7-B7F7-49BF-BB28-FF1B1A2F7F7FQ40435957-F530AC6D-4322-4D9A-BEB6-2F04F0FE99AEQ42226456-3821EB3E-93AF-4952-AE56-CC1DF70C6861Q44282826-AB52AB21-EC20-47C5-8813-732A1A1DCB98Q45390356-77139D8E-78CB-4DD9-AFEB-2716FDBA60A1Q45417487-CEBF7B1C-53B0-40AE-9976-8912D274980DQ45610729-2819A853-DF0D-4922-82BA-246F4E1B6338Q45985731-4CA5E2BC-54AF-4CF1-B87C-956213F99A43Q47340934-958531E5-7663-48FB-A4E6-16528A29DB36Q51839697-2FD9EAD3-12FB-48B7-9351-78A1F992034BQ57193627-963BE35E-9742-4B78-9647-C74CF4E01005Q57814647-DEEDFB0C-4E08-4AF3-9E74-6C0063A6E054Q57816687-38CD9570-DB47-4181-B12C-6C9E4AD8C14DQ58089550-F37ADCAA-DDF0-4D6B-AAE1-D0B48E1D572CQ58382353-0F3EFAD7-99CA-4315-AAA1-83DA7E00C38EQ64102134-262DAAC5-0CF6-428C-B744-DD9B3DD179C5Q85175130-E86101AE-F3B0-49B4-95BB-3AD169E8ACC0
P50
name
Othmar G Engelhardt
@en
type
label
Othmar G Engelhardt
@en
prefLabel
Othmar G Engelhardt
@en